posted on 2021-08-11, 15:55authored byChristine Gyldenkerne, Jakob S. Knudsen, Kevin K. W. Olesen, Henrik T. Sørensen, Hans E. Bøtker, Reimar W. Thomsen, Michael Maeng
OBJECTIVE Trends in cardiac risk and death have not been examined in
patients with incident type 2 diabetes and no prior cardiovascular disease.
Therefore, we aimed to examine trends in cardiac risk and death in relation to
use of prophylactic cardiovascular medications in patients with incident
type 2 diabetes without prior cardiovascular disease.
<p>RESEARCH DESIGN AND METHODS In this population-based cohort study, we
included patients with incident type 2 diabetes between 1996 and
2011 through national health registries. Each patient was matched by age and
sex with up to 5 persons without diabetes from the general population. All individuals
were followed for 7 years.</p>
<p>RESULTS We identified 209,311 patients with incident diabetes. From 1996-1999
to 2008-2011, the
7-year risk of myocardial infarction decreased from 6.9% to 2.8% (adjusted hazard ratio [aHR] 0.39, 95% CI 0.37-0.42), cardiac
death from 7.1% to 1.6% (aHR 0.23, 95% CI 0.21-0.24), and all-cause death from
28.9% to 16.8% (aHR 0.68, 95% CI 0.66-0.69). Compared to the general
population, 7-year risk differences decreased from 3.3% to 0.8% for myocardial
infarction, from 2.7% to 0.5% for cardiac death, and from 10.6% to 6.0% for all-cause
death. Use of cardiovascular medications within ±1 year of diabetes
diagnosis, especially
statins (5% users in 1996-1999 vs. 60% in 2008-2011), increased during the
study period.</p>
<p>CONCLUSIONS From 1996 to 2011, Danish patients with incident type 2
diabetes and no prior cardiovascular disease experienced major reductions in
cardiac risk and mortality. The risk reductions coincided with increased use of
prophylactic cardiovascular medications. </p>
<br>
<p> </p>
Funding
This work was supported by the Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.